Human Metabolome Technologies Hires VP, Business and Product Development

“I am excited that Alex will be joining our team,” said Hoshiba. “Dr. Buko brings with him over 30 years of pharmaceutical experience with the FDA, Abbott Labs, and most recently with Biogen Idec where he held the position of Senior Director of Translational Medicine. Alex has successfully led large scale omics projects in neurology, immunology and oncology. With extensive experience in protein and metabolite based profiling, Alex will lead project management and develop HMT’s biomarker based platforms.” “I am very honored to join HMT and look forward to working with the research teams in both academia and pharmaceutical companies to further enrich metabolic research,” said Buko. “HMT’s commitment to delivering quantitative and metabolic profiling will set the standard for discovery research to come.”

HMT is also pleased to announce F-SCOPE, a new C13 metabolite profiling platform. “F-SCOPE is the only quantitative C13 profiling assay commercially available,” says Dr. Laura Shelton, the Scientific Project Coordinator. “This assay allows for the quantitative detection of over 55 labeled metabolites involved in central energy metabolism including glycolysis, the TCA cycle, amino acids, purines, and glutathione, reporting C13 and C12 fractions for full flux and pathway based analyses.” “F-SCOPE is ideal for analyzing biochemical networks and metabolic perturbations,” says Dr. Buko. “The addition of F-SCOPE to CARCINOSCOPETM and other HMT services will provide another cutting edge quantitative research tool. The capability to deliver unique quantitative and comparative metabolomics profiles is the hallmark of HMT.”